Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Roma
Clinical trial register · Italy

Clinical Trials in Roma, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 73 Roma 52 Rozzano 26 Florence 24 Ancona 24
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS197 AstraZeneca72 Novartis Pharmaceuticals52 Janssen Research & Development, LLC44 Merck Sharp & Dohme LLC43 Clear sponsor filter
Site location
Milan73 Roma52 Rozzano26 Florence24 Ancona24
All 66 locations
Target enrolment
to

Trials with a site in Roma

52 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
60
Florence, Roma, Trieste, Vicenza
2026-06-26
Active, closed
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
DrugsTNO155·Opnurasib·Trametinib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
25
Milan, Roma
2026-06-08
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Milan, Roma
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Meldola, Florence, Padova, Roma, Verona, Novara
2026-05-27
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Roma
2026-04-28
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Florence, Milan, Roma
2026-03-09
Recruiting
Novartis Pharmaceuticals
Observational
50
Alessandria, Avellino, Brescia, Florence, Genova, Milan, Palermo, Roma
2026-01-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Ancona, Bergamo, Foggia, Pozzilli, Pavia, Roma, Gallarate, Naples
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Florence, Genova, Roma
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Roma, Torino, Trieste
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Genova, Roma
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Bergamo, Foggia, Genova, Milan, Pavia, Roma
2025-06-23
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Cona, Genova, Milan, Rozzano, Pisa, Roma
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Milan, Roma, Torino, Verona
2024-12-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Foggia, Monza, Palermo, Pavia, Roma, Sassari, Ivrea, Trieste
2024-10-24
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Ancona, Milan, Rozzano, Modena, Palermo, Pavia, Roma, Verona
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Bologna, Florence, Genova, Milan, Palermo, Roma, Orbassano
2024-07-31
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Cona, Pisa, Roma, Torino
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Brescia, Cona, Genova, Milan, Rozzano, Pisa, Roma, Negrar
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Ranica, Milan, Roma
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Genova, Milan, Roma, Naples
2024-01-03
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Bologna, Milan, Roma, Torino, Naples
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Milan, Rozzano, Modena, Roma, Siena
2023-11-15
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Bari, Ranica, Brescia, Milan, Roma, Torino, Naples
2023-10-02
Recruiting
Novartis Pharmaceuticals
Phase 3
200
Brescia, Catania, Florence, Pavia, Roma, Naples
2023-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Ancona, Cona, Padova, Pisa, Roma, Torino
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Brescia, Florence, Genova, Milan, Roma
2023-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Milan, Modena, Roma
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Bologna, Florence, Roma, Trieste, Vicenza
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Bologna, Roma, Trieste
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Roma
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Bari, Rozzano, Roma, Orbassano
2022-12-06
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Meldola, Milan, Pisa, Roma, Torino
2022-11-21
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Milan, Roma, Naples
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
95
Lucca, Aviano, Roma
2022-06-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Genova, Monza, Roma, Torino
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Milan, Roma, Verona, Novara
2021-12-16
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bologna, Milan, Reggio Emilia, Roma, Verona
2021-10-06
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Roma, Naples
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Ranica, Milan, Roma
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Ascoli Piceno, Avellino, Florence, Milan, Roma, Torino, Bassano del Grappa
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 2
236
Roma, Torino
2021-04-19
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Roma
2021-03-15
Active, closed
Novartis Pharmaceuticals
Phase 2
17
Roma
2020-12-18
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Florence, Genova, Milan, Roma, Torino
2019-11-04
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Bari, Ranica, Roma
2019-10-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bologna, Milan, Roma, Rozzano
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 2
121
Roma
2019-06-24
Active, closed
Novartis Pharmaceuticals
Phase 2
22
Pavia, Roma, Torino, Naples
2019-03-13
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Bari, Bologna, Pavia, Roma, Siena
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Bologna, Monza, Milan, Rozzano, Roma
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Bari, Montichiari, Catania, Milan, Cefalù, Roma, Gallarate
2013-07-26
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-italy/city/roma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Roma that also match the filters currently applied.

How many clinical trials are recruiting in Roma?

27 of the 52 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Roma), 52 studies
PhaseStudiesRecruitingShare
Phase 3291555.8%
Phase 215628.8%
Phase 1/2437.7%
Phase 4213.8%
Observational111.9%
Phase 2/3111.9%

Most active sponsors

Lead sponsors with the most studies (Roma)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals5227
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.